Anavex Completes Clinical Conduct of Two Blarcamesine Pharmacology Studies

• Anavex Life Sciences completed two blarcamesine clinical pharmacology studies intended to support its FDA-focused Alzheimer’s disease development program.
• Preliminary findings showed no serious adverse events; full safety and pharmacokinetic analyses remain ongoing.
• The FDA cleared blarcamesine’s Fragile X syndrome trial application, as announced October 15, 2026; study start-up activities are underway.
• A November FDA meeting will address adding pediatric participants to the Phase 3 Rett syndrome trial, which currently covers adults.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610201600PRIMZONEFULLFEED9849732) on October 20, 2026, and is solely responsible for the information contained therein.